

NOVO NORDISK A S  
Form 6-K  
March 21, 2011

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

**March 21, 2011**

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_



## Company Announcement

21 March 2011

### Novo Nordisk A/S – Share repurchase

On 2 February 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 2 February 2011 to 26 April 2011.

Since the announcement as of 14 March 2011, the following transactions have been made under the programme:

|                          | <b>Number of</b>             | <b>Average Transaction value,</b> |                      |
|--------------------------|------------------------------|-----------------------------------|----------------------|
|                          | <b>shares purchase price</b> |                                   | <b>DKK</b>           |
| <b>Accumulated, last</b> |                              |                                   |                      |
|                          | 1,467,000                    |                                   | 962,952,732          |
| <b>announcement</b>      |                              |                                   |                      |
| 14 March 2011            | 43,000                       | 663.1265                          | 28,514,440           |
| 15 March 2011            | 53,500                       | 645.2891                          | 34,522,967           |
| 16 March 2011            | 79,500                       | 645.9910                          | 51,356,285           |
| 17 March 2011            | 50,000                       | 640.6792                          | 32,033,960           |
| 18 March 2011            | 45,000                       | 651.1000                          | 29,299,500           |
| <b>Accumulated under</b> |                              |                                   |                      |
|                          | <b>1,738,000</b>             |                                   | <b>1,138,679,882</b> |
| <b>the programme</b>     |                              |                                   |                      |

With the transactions stated above, Novo Nordisk owns a total of 28,948,482 treasury shares, corresponding to 4.8% of the share capital. The total amount of shares in the company is 600,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares worth DKK 10.0 billion during 2011. As of 18 March 2011, Novo Nordisk has repurchased a total of 1,738,000 B shares equal to a transaction value of DKK 1,138,679,882.

Company Announcement no 17 / 2011

Page 1 of 2

|                         |               |               |                 |          |
|-------------------------|---------------|---------------|-----------------|----------|
| <b>Novo Nordisk A/S</b> | Novo Allé     | Telephone:    | Internet:       | CVR no:  |
| Investor Relations      | 2880 Bagsværd | +45 4444 8888 | novonordisk.com | 24256790 |
|                         | Denmark       | Telefax:      |                 |          |
|                         |               | +45 4444 6626 |                 |          |

---

*Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 30,900 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).*

For further information please contact:

Media:

*Outside North America:*  
Anne Margrethe Hauge

Tel: (+45) 4442 3450

[amhg@novonordisk.com](mailto:amhg@novonordisk.com)

Investors:

*Outside North America:*  
Klaus Bülow Davidsen

Tel: (+45) 4442 3176

[klda@novonordisk.com](mailto:klda@novonordisk.com)

Jannick Lindegaard

Tel: (+45) 4442 4765

[jlis@novonordisk.com](mailto:jlis@novonordisk.com)

*In North America:*

Ken Inchausti

Tel: (+1) 609 514 8316

[kiau@novonordisk.com](mailto:kiau@novonordisk.com)

*In North America:*

Hans Rommer

Tel: (+1) 609 919 7937

[hrrmm@novonordisk.com](mailto:hrrmm@novonordisk.com)

Company Announcement no 17 / 2011

Page 2 of 2

**Novo Nordisk A/S** Novo Allé

Telephone:

Internet:

CVR no:

Investor Relations 2880 Bagsværd

+45 4444 8888

[novonordisk.com](http://novonordisk.com)

24256790

Denmark

Telefax:

+45 4444 6626



## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: March 21, 2011

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer

---

